Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasm, Residual × Trastuzumab × 90 days × Clear all

Sponsor

Conditions

Breast Neoplasms 46 Stomach Neoplasms 10 Neoplasm Metastasis 6 Esophageal Neoplasms 6 Neoplasms 5 Colorectal Neoplasms 4 Adenocarcinoma Of Esophagus 4 Colonic Neoplasms 3 Brain Neoplasms 3 Triple Negative Breast Neoplasms 2 Solid Tumors 2 Rectal Neoplasms 2 Multiple Myeloma 2 Meningeal Neoplasms 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Inflammatory Breast Neoplasms 2 HER2-positive Gastric Cancer 2 HER2-positive Early Breast Cancer 2 HER2-positive Breast Cancer 2 Carcinoma, Non-Small-Cell Lung 2 Anatomic Stage I Breast Cancer AJCC v8 2 Adenocarcinoma 2 Uterine Cervical Neoplasms 1 Solid Cancer 1 Salivary Gland Neoplasms 1 Resectable HER2-positive Breast Cancer 1 Prostatic Neoplasms 1 Patient Preference 1 Pathologic Complete Response 1

Interventions

Cyclophosphamide 5 fludarabine 4 Dexamethasone 4 blinatumomab 3 Lenalidomide 3 pembrolizumab 2 fludarabine phosphate 2 Cytarabine 2 venetoclax 1 tislelizumab 1 tisagenlecleucel 1 tetrathiomolybdate 1 tagraxofusp 1 relugolix 1 obinutuzumab 1 nilotinib 1 ixazomib 1 isatuximab 1 inavolisib 1 giredestrant 1 enzalutamide 1 daratumumab 1 abemaciclib 1 Vincristine 1 Transplantation 1 Radiotherapy 1 Neoadjuvant Therapy 1 Monatide (IMS 3015) 1 Methotrexate 1 Melphalan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡